Skip to main content

Table 2 Binding score of each selected peptide for the HLA specificities evaluated

From: Computer-Based Design of an HLA-Haplotype and HIV-Clade Independent Cytotoxic T-Lymphocyte (CTL) Assay for Monitoring HIV-Specific Immunity

  HLA-A HLA-B HLA-C
Peptides A1 A2 A3 A24 A31 A33 A68 B7 B8 B14 B15 B27 B35 B37 B38 B39 B40 B44 B51 B52 B58 B60 B61 B62 Cw3 Cw4 Cw6 Cw7
1.1: EKIRLRPGGKKKYRL 40 42 81 8 40 40 45 70 88 11 26 37 45 18 11
1.2a: PGGKKKYRLKHLVWA 20 41 33 6 34 77 12 32 46 9 27 10 10 10 10 10 7
1.2b: PGGKKKYRMKHLVWA 20 41 33 10 34 52 10 35 46 27 10 10 10 10 10 7
1.3a: KKYRLKHLVWASREL 14 61 37 6 33 10 12 29 40 6 42 43 10 42 45 12 15 11 8 45 11
1.3b: KKYRMKHLVWASREL 14 61 37 6 66 10 12 29 40 6 42 38 10 42 45 12 15 11 8 45 11
1.4: KHLVWASRELERFAV 26 33 46 33 74 37 35 42 38 42 15 45 10 57 8 45
1.5a: RELERFAVNPGLLET 46 61 48 25 6 31 38 45 45 70 12 50 12 39 63 31 18 75 60 8 52
1.5b: RELERFAVDPGLLET 46 58 48 25 34 38 45 42 70 12 50 12 37 63 31 18 75 60 6 52
2.1a: SAPKTGTEELRSLYN 68 47 26 10 18 68 63 45 38 83 47 55 65 67 45 27
2.1b: SALKTGTEELRSLYN 68 47 26 10 18 68 63 45 38 83 47 55 65 67 45 6 27
2.2: EELRSLYNTVATLYC 18 86 53 33 6 37 44 21 41 40 42 10 8 27 47 8 18 38 31 68 88 33 9 15 65
2.3a: SLYNTVATLYCVHQR 38 86 53 22 19 37 32 21 41 32 12 12 8 38 19 21 15 33 9 15 65
2.4b: SLYNTVAVLYCVHQR 38 86 53 22 19 37 32 21 38 32 12 12 8 38 19 21 15 33 9 15 65
3.1: SPRTLNAWVKVIEEK 16 61 26 14 60 37 12 65 22 11 16 38 11 12 12 8 11 45
3.2: KVIEEKAFSPEVIPM 26 36 46 13 37 42 32 43 74 33 29 23 33 67 12 63 9
3.3: EKAFSPEVIPMFSAL 24 44 46 27 39 40 37 24 45 43 74 12 21 25 29 27 78 77 42 63 75 23
3.4: SPEVIPMFSALSEGA 24 44 46 39 40 37 24 45 16 21 21 25 9 27 77 42 8 75
4.1a: ATPQDLNMMLNIVGG 24 75 33 15 60 39 39 38 33 45 18 7 32 12 33 43 33 79
4.1b: ATPQDLNTMLNIVGG 24 75 33 15 57 39 39 38 33 45 18 7 32 12 33 43 33 79
4.2: QDLNMMLNIVGGHQA 14 75 37 20 30 29 45 8 9 12 43 11 79
4.3: MMLNIVGGHQAAMQM 12 42 42 12 34 15 32 38 12 11 7 11 13
5.1: SNPPIPVGDIYKRWI 44 36 46 12 17 12 57 43 21 16 54 66 10 13 55 11 13 10 12 57
5.2: GDIYKRWIILGLNKI 16 75 35 59 12 17 31 52 66 39 54 72 63 73 21 7 85 16 9 56 80 20
5.3: KRWIILGLNKIVRMY 36 75 56 44 78 12 23 25 8 19 46 8 63 9 81 81 100 27
5.4a: LGLNKIVRMYSPVSI 36 44 42 8 6 23 25 7 16 46 24 15 9 9 81 42 27
5.4b: LGLNKIVRMYSPTSI 36 44 42 8 6 23 25 7 16 46 24 8 9 9 81 42 27
5.5a: RMYSPVSILDIKQGP 24 66 28 37 43 42 39 30 33 62 32 16 31 10
5.5b: RMYSPTSILDIKQGP 24 66 28 37 43 42 39 30 33 62 32 16 31 10
  1. The percentage of the maximum binding of any allele belongs to a HLA class I serologic specificity analyzed is reported for all the designed peptides. HLA class I serologic specificities are grouped per HLA locus (HLA-A, -B, -C). Peptides are listed on the left and numbered according to the area of GAG protein (see Fig. 1). Peptides shared the same base sequence are listed with the same number followed by a different letter. Prediction values below 5% are indicated with a dot, between 5–29% are reported with normal character, between 30–49% are underlined, higher than 50% of the maximum binding are bolded.